Latvija -
latviešu -
Zāļu valsts aģentūra
caduet 5 mg/10 mg apvalkotās tabletes
upjohn eesv, netherlands - amlodipinum, atorvastatinum - apvalkotā tablete - 5 mg/10 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
caduet 10 mg/10 mg apvalkotās tabletes
pfizer europe ma eeig, united kingdom - amlodipinum, atorvastatinum - apvalkotā tablete - 10 mg/10 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
caduet 5 mg/10 mg apvalkotās tabletes
pfizer europe ma eeig, united kingdom - amlodipinum, atorvastatinum - apvalkotā tablete - 5 mg/10 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
caduet 10 mg/10 mg apvalkotās tabletes
upjohn eesv, netherlands - amlodipinum, atorvastatinum - apvalkotā tablete - 10 mg/10 mg
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
dapagliflozin viatris
viatris limited - dapagliflozīns - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
edistride
astrazeneca ab - dapagliflozin propāndiols monohidrāts - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. papildus citām zālēm, lai ārstētu 2. tipa cukura diabētu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
forxiga
astrazeneca ab - dapagliflozin propāndiols monohidrāts - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - cukura diabēts - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. papildus citām zālēm, lai ārstētu 2. tipa cukura diabētu. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
possia
astrazeneca ab - tikagrelors - peripheral vascular diseases; acute coronary syndrome - antitrombotiskie līdzekļi - possia, pārvalda kopīgi ar acetilsalicilskābes (asa), ir norādīts aterotrombotiskām notikumiem pieaugušiem pacientiem ar akūtu koronārā sindroma (nestabilu stenokardiju, st pacēlums miokarda infarkta [nstemi] vai st pacēlums novēršanai miokarda infarkta [stemi]); tajā skaitā pārvalda medicīniski pacientiem un tiem, kuri tiek pārvaldīti ar koronāro perkutānā toksicitāte iejaukšanās (pci) vai koronāro artēriju apvedlīnijas potēšanas (cabg).
Latvija -
latviešu -
Zāļu valsts aģentūra
regiocit šķīdums hemofiltrācijai
baxter holding b.v., netherlands - natrii citras, natrii chloridum - Šķīdums hemofiltrācijai